Effects of GABA Modulator AZD7325 on Cortical Excitability

NCT ID: NCT02135198

Last Updated: 2015-08-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-09-30
• Study Completion Date: 2015-08-31

Brief Summary

GABA (gamma-aminobutyric acid) is the main inhibitory compound in the human brain. Drugs that enhance its effects by binding on GABA receptors (e.g., benzodiazepines) are used to treat various diseases such as epilepsy, insomnia, anxiety or movement disorders. However, the use of these medications is often compromised due to their side effects, like sedation, cognitive impairment, and addiction.

Many of these side effects have been linked to a particular type of GABA receptor (GABA A alpha 1). Therefore, effort is being made to develop drugs that do not act on this receptor, but maintain their beneficial properties by acting on other types of GABA receptors. AZD7325 is a drug that selectively acts on GABA A alpha 2 and A alpha 3 receptors, but not A alpha 1. It has been tested in more than 700 people and so far proved to be generally well tolerated. Positron emission tomography (PET) study in humans demonstrated that AZD7325 binds to GABA A receptors in the brain after a single dose. Early clinical studies have shown that it has less sedative and cognitive adverse events as compared with a benzodiazepine lorazepam.

In this study, we will investigate its effects on short interval intracortical inhibition (SICI). SICI is neurophysiological marker of inhibitory processes in the motor cortex. It is obtained non-invasively by using transcranial magnetic stimulation (TMS). In TMS, magnetic impulses applied over the scalp that in turn induce a current in a small area of the brain. If applied over the motor areas of the brain, impulses result in muscle twitch that is recorded with surface electrodes. SICI is enhanced by certain drugs like benzodiazepines that act on GABA A alpha 1,2,3, and 5 receptor subtypes, but not by zolpidem acting solely on alpha 1 subtype. Because GABA A alpha 5 receptor subtype is less common in the cortex, it has been concluded that the drug effects on SICI are related to GABA A alpha 2 and alpha 3 receptors.

If AZD7325 proves to enhance SICI in healthy volunteers, this would create the grounds for the use of this medication to treat certain neurological disorders in which SICI has been found to be impaired (e.g., dystonia).

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

2 mg AZD7325

2 mg AZD7325 in orange capsule, Size 0, single oral dose

Group Type: EXPERIMENTAL

2 mg AZD7325

Intervention Type: DRUG

A single 2 mg oral dose of AZD7325

10 mg AZD7325

Intervention Type: DRUG

A single 10 mg oral dose of AZD7325

Placebo

Intervention Type: DRUG

A single oral dose

10 mg AZD7325

10 mg AZD7325 in orange capsule, Size 0, singe oral dose

Group Type: EXPERIMENTAL

2 mg AZD7325

Intervention Type: DRUG

A single 2 mg oral dose of AZD7325

10 mg AZD7325

Intervention Type: DRUG

A single 10 mg oral dose of AZD7325

Placebo

Intervention Type: DRUG

A single oral dose

Placebo

10 mg Microcrystalline cellulose in orange capsule, Size 0, single oral dose

Group Type: PLACEBO_COMPARATOR

2 mg AZD7325

Intervention Type: DRUG

A single 2 mg oral dose of AZD7325

10 mg AZD7325

Intervention Type: DRUG

A single 10 mg oral dose of AZD7325

Placebo

Intervention Type: DRUG

A single oral dose

Interventions

2 mg AZD7325

A single 2 mg oral dose of AZD7325

Intervention Type: DRUG

10 mg AZD7325

A single 10 mg oral dose of AZD7325

Intervention Type: DRUG

Placebo

A single oral dose

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male adults aged 18 to 55 years (extremes are included)
• A body weight resulting in a body mass index (BMI) of 18 - 30 kg/m2 (extremes included) using the formula BMI = body-weight [in kg] / body-height [in m]2
• Able and willing to sign the Informed Consent Form prior to screening evaluations
• History of good physical and mental health as determined by history taking and laboratory examinations, ECG, blood pressure and heart rate recordings as judged by the investigator
• Willing not to consume alcohol or to smoke or chew tobacco on days of assessments
• Subjects must be willing to avoid unprotected sex or donating sperm until 3 weeks after drug administration

Exclusion Criteria

• History of sensitivity/idiosyncrasy to AZD7325 or chemically related compounds or excipients which may be employed in the study or to any other drug used in the past
• Subject has taken systemically any potent or moderate CYP3A4 or CYP2C9 inhibitor, 1 month prior to screening (topical or inhaled are permitted) such as: aprepitant, barbiturates, carbamazepine, clarithromycin, erythromycin, cyclosporine, diltiazem, efavirenz, fluconazole, HIV protease inhibitors, glucocorticoids, itraconazole (oral/IV), ketoconazole, nefazodone, nevirapine, phenytoin, pioglitazone, primidone, rifabutin, rifampicin, telithromycin, St. John's wort, verapamil
• Use of any prescription drug within two weeks prior to the first dosing, except for topical medication without systemic exposure
• Clinically relevant history or presence of any medical disorder, potentially interfering with this trial
• Clinically relevant abnormal laboratory, ECG, HR or BP at screening as judged by the investigator
• History of or current abuse of drugs (including prescription medication) or alcohol or solvents
• Smoking in excess of 5 cigarettes per day or the equivalent within 28 days prior to the first study day
• Smoking or chewing of tobacco or consuming of alcohol 24 hours before and on the days of assessment
• Subject is family member or in the employment line management of study personnel
• Subject's partner is planning pregnancy within 3 months of last dosing
• Participation in an investigational medicinal product (IMP) intervention trial within last month or more than four in the previous 12 months
• Abnormal SICI response, kinematic analysis of circle drawing, SDMT, VAS outside 95% confidence interval of normal at screening visit
• Contraindications for TMS

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

University College, London

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Martin Koltzenburg, Prof

Role: PRINCIPAL_INVESTIGATOR

Institute of Neurology, University College London

Locations

National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust

London, , United Kingdom

Countries

United Kingdom

Other Identifiers

2013-005472-17

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

13/0231

Identifier Type: -

Identifier Source: org_study_id